MOF@siRNA-loaded exosomes and their applications
By coating the extracellular vesicle structure of siRNA vector, the biological affinity and delivery efficiency of MOF@siRNA are improved, and the problem of easy removal and low delivery efficiency of MOF molecules in the prior art is solved, achieving more Good tumor targeted treatment effect.
Patent Information
- Application Number
- CN202310939827.8
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2023-07-28
- Publication Date
- 2024-11-15
- Estimated Expiration
- 2043-07-28
AI Technical Summary
Existing siRNA delivery systems have problems with poor biosafety and low delivery efficiency, especially metal-organic framework (MOF) molecules are easily removed by the immune system in the organism, resulting in short half-life and insufficient accumulation of target tissues.
Extracellular vesicles (EVs) derived from probiotic Lactobacillus acidophilus are coated with MOF@siRNA-loaded nanoparticles to improve the biological affinity and delivery effect of drug molecules through biofilm structure.
It improves the uptake efficiency and release effect of MOF@siRNA in tumor cells, extends the half-life in blood circulation, enhances the accumulation of tumor tissues, and improves the application effect of tumor prevention and treatment.
Smart Images

Figure FT_1 
Figure FT_2 
Figure FT_3
Abstract
Description
Technical Field
[0001] The present application belongs to the technical field of tumor prevention and treatment, and specifically relates to an exosome loaded with MOF@siRNA and its application. Background Art
[0002] With the deepening of human genomics research, gene therapy for various complex diseases (such as cancer, genetic diseases, etc.) has also emerged. With the deepening of various gene therapy research, RNA interference (RNAi) technology as a post-transcriptional gene regulation technology has also been widely used in the treatment of various cancers. Its technical principle is mainly to inhibit the mining of oncogenes and the translation and expression of corresponding mRNA through specific inhibition, thereby inhibiting the proliferation and migration of tumors.
[0003] In the prior art, there are delivery systems constructed using liposomes, polymers, etc. to address the delivery problem of siRNA. However, due to differences in siRNA molecular size and delivery sites, there is currently no good universal delivery system. In addition, existing siRNA delivery systems also have certain problems such as poor safety and low delivery efficiency. Therefore, how to improve the biosafety and loading efficiency of related siRNA carriers has become a technical problem that needs to be urgently solved in the research and development of siRNA delivery systems.
[0004] Metal-organic framework (MOF) is a new type of nanomolecular structure. It has been increasingly studied and applied in the field of drug delivery carriers due to its high porosity, high loading rate, easy synthesis, and excellent cell permeability. Among them, UiO-66-NH2 is a MOF structure molecule that has been studied more.
[0005] UiO-66-NH2 is a nanoscale metal organic framework (nMOF) formed by the coordination of Zr metal ions and two oxygen atoms on the carboxyl group of terephthalic acid containing amino groups. When used as a drug carrier, drug loading can be achieved by stirring at room temperature. In addition, UiO-66-NH2 has good pH sensitivity and can effectively release the loaded drugs even in the acidic environment of tumor cells, thereby exerting anti-tumor activity. However, actual animal application experiments also show that since UiO-66-NH2 nanoparticles are exogenous substances, they are easily quickly cleared by the immune system in animal organisms. Therefore, how to prolong the half-life of such MOF molecules in the blood circulation process and enhance their accumulation in the target (tumor) tissue site is a technical problem that must be solved to improve the application effect of MOF molecules. Summary of the invention
[0006] The purpose of this application is to use EVs with a biomembrane structure to encapsulate and carry related nanomaterials, thereby laying a certain technical foundation for improving the application effect of related drug molecules.
[0007] The technical solution adopted in this application is described in detail as follows.
[0008] An exosome loaded with MOF@STAT3 siRNA is prepared by the following steps:
[0009] 1. Design of siRNA
[0010] For CRC, the corresponding siRNA is designed as follows:
[0011] Sense sequence (shown in SEQ ID No. 1): 5'-AAUUUUAAGCUGAUAAUUCAA-3';
[0012] Anti-sense sequence (shown in SEQ ID No. 2): 5'-GAAUUAUCAGCUUAAAAUUAA-3';
[0013] Target sequence: 5′- TTGAATTATCAGCTTAAAATTAA-3′;
[0014] (II) Preparation of UiO-66-NH2 with MOF structure
[0015] UiO-66-NH2 is a metal-organic framework (MOF) molecular structure. The specific preparation operation is as follows:
[0016] First, 110 mg of 2-aminoterephthalic acid, 1.9 g of benzoic acid, and 120 mg of zirconium tetrachloride were added to 10 mL of DNF and sonicated for 5 min to completely dissolve them;
[0017] Subsequently, the mixed solution was transferred into a 100 mL high-pressure reactor, and the reactor was tightened and placed in a forced air drying oven to react at 120°C for 24 h. After the reaction was completed, the mixture was naturally cooled to room temperature.
[0018] Then, the reactor was opened to take out the solution inside, centrifuged at 8000 rpm for 10 min, and the precipitate was washed with ethanol three times;
[0019] Finally, the precipitate after washing with ethanol was placed in a vacuum drying oven at 65 °C for 12 h, and the obtained material was a light yellow crystalline UiO-66-NH2.
[0020] (III) Preparation of UiO-66-NH2@siRNA
[0021] 1 mg of UiO-66-NH2 prepared in step (ii) and 500 nM of siRNA prepared in step (i) were mixed and dissolved in DEPC water, and stirred at room temperature for 24 h to ensure that siRNA could be fully loaded on UiO-66-NH2;
[0022] Subsequently, the mixture was centrifuged at 8000 rpm for 10 min, and the precipitate was washed repeatedly with DEPC water for 3 times;
[0023] Finally, the cleaned sample was placed in a vacuum drying oven and dried at 65 °C for 12 h to obtain UiO-66-NH2@siRNA nanoparticles loaded with siRNA.
[0024] (IV) Extracellular vesicles (EVs) loaded with MOF@STAT3 siRNA
[0025] The probiotic Lactobacillus acidophilus was used as the source of extracellular vesicles (EVs) to prepare L. acidophilus ) Extracellular vesicles EVs from
[0026] The prepared EVs (0.5 mg / mL, 1 mL) were mixed with the UiO-66-NH2@siRNA nanoparticles (1 mg / mL, 1 mL) prepared in step (iii) above using PBS solution (pH=7.4) and treated with ultrasound (ultrasonic frequency: 40KHZ) for 30 min;
[0027] Subsequently, the mixed solution was transferred into a liposome extruder and extruded through polycarbonate membranes with pore sizes of 800 nm, 400 nm, 200 nm and 100 nm, respectively. After repeating this extrusion operation 11 times, the obtained extrudate solution was centrifuged at 12,000 rpm for 5 min, and the precipitate was EVs@UiO-66-NH2@siRNA nanoparticles, which were further resuspended in PBS solution.
[0028] The Lactobacillus acidophilus ( L. acidophilus The specific preparation procedures of extracellular vesicles EVs from ) are as follows:
[0029] (1) Recovery and initial expansion of strains
[0030] The original source of Lactobacillus acidophilus stored (-80℃) was streaked on MRS solid medium and cultured at 37℃ for about 48 h for recovery; after a single colony grew, a single colony was picked and transferred to 4 mL MRS liquid medium, cultured at 37℃ for 24 h, and then 4 mL of bacterial liquid was inoculated into 400 mL MRS liquid medium and cultured for 24 h (OD 600= about 0.8) for preliminary amplification of the strain;
[0031] (2) Extraction of extracellular vesicles (EVs)
[0032] First, take 2000 mL of the amplified bacterial solution in step (1) above, centrifuge at 4°C and 100,000 g for 30 min, and discard the precipitate;
[0033] Subsequently, the supernatant was centrifuged at 100,000 g for 60 min at 4°C, and the precipitate was retained;
[0034] Then, the precipitate was resuspended in 5 mL of PBS solution and centrifuged again at 4°C and 100,000 g for 60 min to retain the precipitate;
[0035] Finally, the precipitate was resuspended in 1 mL of PBS solution to obtain the Lactobacillus acidophilus EVs solution.
[0036] Colorectal cancer (CRC) is one of the common malignant tumors. Studies have shown that signal transducer and activator of transcription protein 3 (STAT3) can inhibit cell apoptosis and promote tumorigenesis, and is considered an important therapeutic target in the prevention and treatment of CRC. Experiments have shown that STAT3 siRNA based on the STAT3 target has shown good application potential in the treatment of chemically induced in situ CRC mouse models. Although the gene silencing method based on the STAT3 target is an effective strategy for CRC treatment, there are still many technical obstacles in how to accurately deliver the corresponding therapeutic STAT3 siRNA drug to the treatment site.
[0037] In this application, taking siRNA specifically for the prevention and treatment of CRC as an example, in order to improve its application effect, it is first loaded on a metal-organic framework (MOF) UiO-66-NH2, which helps to improve the application effect of siRNA. However, since the MOF loaded with siRNA is still a "foreign substance" in the body, it is easily cleared out of the body by the body's immune system. Therefore, improving the bio-affinity of this material is a technical problem that must be solved.
[0038] Using biofilm to cover "foreign substances" to form a cell-mimetic structure is a good biological strategy to improve the affinity between "foreign substances" and organisms, but the selection of biofilm materials, safety, coating ability, etc. need to be reasonably selected according to the characteristics of the "foreign substances".
[0039] In this application, based on safety and availability, the inventors selected extracellular vesicles EVs from the probiotic Lactobacillus acidophilus as the source of biofilm, and further coated the composite MOF@STAT3 siRNA (UiO-66-NH2@STAT3 siRNA) with Lactobacillus acidophilus EVs. Preliminary experimental results show that colon cancer target cells have a good uptake effect on the MOF@STAT3siRNA encapsulated by the EVs, and can release STAT3siRNA well after uptake, thus laying a good technical foundation for the prevention and treatment of colon cancer.
[0040] In general, the drug delivery system constructed in the present application makes better use of the loading effect of metal-organic framework molecules on related drug molecules, while making better use of the biological affinity of the biomembrane structure of extracellular vesicles EVs, which is beneficial to improving and enhancing the application effect of drug molecules, thereby laying a good technical foundation for the prevention and treatment of related tumors. BRIEF DESCRIPTION OF THE DRAWINGS
[0041] Figure 1 TEM images of EVs, UiO-66-NH2, UiO-66-NH2@siRNA, and EVs@UiO-66-NH2@siRNA;
[0042] Figure 2 Particle size (A) and Zeta (B) potential of EVs, UiO-66-NH2, UiO-66-NH2@siRNA, and EVs@UiO-66-NH2@siRNA;
[0043] Figure 3 is the encapsulation efficiency under different siRNA concentrations;
[0044] Figure 4 Powder XRD spectra of simulated UiO-66-NH2, synthesized UiO-66-NH2, and UiO-66-NH2@siRNA (A) and nitrogen adsorption-desorption curves of UiO-66-NH2 and UiO-66-NH2@siRNA (B);
[0045] Figure 5 UiO-66-NH2@siRNA and EVs@UiO-66-NH2@siRNA were taken up by MC38 cells after being co-incubated with MC38 cells for 3 h, 8 h, and 12 h, respectively (scale bar = 36.8 μm); color view: cell nucleus, blue; lysosome, red; siRNA, green;
[0046] Figure 6 Nanoparticles inhibit the proliferation of MC38 cells (*** P <0.001);
[0047] Figure 7 After UiO-66-NH2@siRNA and EVs@UiO-66-NH2@siRNA were co-incubated with MC38 cells for 3 h, 8 h, and 12 h, the FAM fluorescence intensity in the cells was detected by flow cytometry;
[0048] Figure 8 After UiO-66-NH2@siRNA and EVs@UiO-66-NH2@siRNA were co-incubated with MC38 cells for 3 h, 8 h, and 12 h, the FAM fluorescence intensity in the cells was quantitatively analyzed (*** P <0.001);
[0049] Fig. 9 Nanoparticles inhibit the proliferation of MC38 cells (*** P <0.001);
[0050] Fig.10 After the nanoparticles were co-incubated with MC38 for 72 h, the absorbance value at OD 450 was quantitatively analyzed (*** P <0.001). DETAILED DESCRIPTION
[0051] The present application is further explained below in conjunction with the embodiments. Before introducing the specific embodiments, some experimental backgrounds in the following embodiments are briefly introduced as follows.
[0052] Biomaterials:
[0053] Lactobacillus acidophilus (strain number: 1.1878) was purchased from China General Microbiological Strains Collection Center;
[0054] Mouse colon cancer MC38 cells were purchased from the Shanghai Cell Bank of the Chinese Academy of Sciences;
[0055] Main reagents:
[0056] Zirconium tetrachloride (ZrCl4), 2-aminoterephthalic acid (NH2-BDC), N, N-dimethylformamide (DNF), benzoic acid, etc. were purchased from Shanghai Sigma;
[0057] STAT3 siRNA, FAM fluorescent labeling, etc. were provided by Shanghai Qingke Biosynthesis;
[0058] BCA protein concentration assay kit, DMEM medium, trypsin, lysozyme, DEPC water, EDTA, sucrose, etc. were purchased from Beijing Solebao;
[0059] Fetal bovine serum was purchased from Shanghai Taier Company;
[0060] DAPI and LysoTracker were purchased from Shanghai Bio-Tech;
[0061] CCK-8 kit, a product of Japan Tongren Co., Ltd.
[0062] MRS liquid culture medium: casein 1.0%, beef extract 10%, yeast extract 0.5%, glucose 2.0%, sodium acetate 0.5%, diammonium citrate 0.2%, Tween 80 0.1%, dipotassium hydrogen phosphate 0.2%, magnesium sulfate heptahydrate 0.02%, manganese sulfate heptahydrate 0.005%, pH 6.2-6.4, sterilization at 121℃ for 20min;
[0063] MRS solid medium: Add 2.0% calcium carbonate and 2.0% agar powder to the liquid medium and sterilize at 121℃ for 20 min;
[0064] PBS (pH = 7.4): weigh 0.2 g KCl, 0.24 g KH2PO4, 8.0 g NaCl, and 3.63 g Na2HPO4·12H2O and dissolve them in 1 L double distilled water. Autoclave at 121°C for 20 min and store at 4°C.
[0065] Main instruments and equipment:
[0066] Laser confocal microscope (LEICA TCS SP8 STED), a product of Leica, Germany;
[0067] Flow cytometer (LSRFortessa), a product of BD, USA;
[0068] Transmission electron microscope (HT7700), produced by Hitachi, Japan;
[0069] Malvern Nano Particle Size Potentiometer (Zetasizer Nano S), a product of Zetasizer Nano S of Germany;
[0070] Liposome extruder (LiposoEasy LE-1), a product of Shanghai Moge Company;
[0071] Polycarbonate porous membrane (GTTP04700) for preparing vesicles, a product of Millipore, Germany;
[0072] X-ray diffractometer (D8 DISCOVER), a product of Bruker, Germany;
[0073] Fully automatic specific surface area measuring instrument (TriStar II), a product of Mack Company, USA.
[0074] Example 1
[0075] The main technical idea of this application is to use biofilm materials to wrap the relevant drug carriers carrying drug molecules, so that it can be used as an organic biomimetic structure, and finally achieve the purpose of increasing its half-life in the blood circulation. In actual research, combined with the inventor's relevant research work experience, the inventor uses a vesicle form with a biofilm to wrap the "drug carrier carrying drug molecules" to coat it. At the same time, from the perspective of biosafety, the inventor believes that the use of extracellular vesicles (EVs) derived from probiotics as a source of biofilm has good application prospects. Therefore, this embodiment first briefly introduces the preparation process of the relevant extracellular vesicles (EVs) as follows.
[0076] Lactobacillus acidophilus ( L. acidophilus ) is a probiotic that is used in a variety of foods (such as yogurt), so it is relatively safe. L. acidophilus ) source of extracellular vesicles, please refer to the following for specific operations.
[0077] 1. Recovery and initial expansion of strains
[0078] The original source of Lactobacillus acidophilus stored (-80℃) was streaked onto MRS solid medium and cultured at 37℃ for about 48 hours for recovery. After a single colony grew, a single colony was picked and transferred to 4 mL of MRS liquid medium. After culturing at 37℃ for 24 hours, 4 mL of the bacterial liquid was inoculated into 400 mL of MRS liquid medium and cultured for 24 hours (OD 600 = about 0.8) for preliminary amplification of the strain.
[0079] 2. Extraction of extracellular vesicles (EVs)
[0080] First, take 2000 mL of the bacterial solution treated in step (ii) above, centrifuge at 4°C and 100,000 g for 30 min, and discard the precipitate;
[0081] Subsequently, the supernatant was centrifuged at 100,000 g for 60 min at 4°C, and the precipitate was retained;
[0082] Then, the precipitate was resuspended in 5 mL of PBS solution and centrifuged again at 4°C and 100,000 g for 60 min to retain the precipitate;
[0083] Finally, the precipitate was resuspended in 1 mL of PBS solution to obtain the Lactobacillus acidophilus EVs solution.
[0084] Example 2
[0085] As a therapeutic drug molecule, this application takes CRC as an example and designs and prepares relevant siRNA for the STAT3 site. As a drug molecule carrier, this application takes UiO-66-NH2 as an example and prepares relevant nanocarriers. The relevant preparation process is briefly described as follows.
[0086] 1. siRNA design
[0087] STAT3 siRNA (sense: 5'-AAUUUUAAGCUGAUAAUUCAA-3')
[0088] STAT3 siRNA (anti-sense: 5'-GAAUUAUCAGCUUAAAAUUAA-3')
[0089] STAT3 target sequence: 5'-TTGAATTATCAGCTTAAAATTAA-3'
[0090] To facilitate detection applications, the synthesized siRNA was further modified with FAM fluorescence, and the relevant sequence and FAM-siRNA sequence after FAM modification were synthesized and provided by Qingke Biotechnology Co., Ltd.
[0091] (II) Preparation of UiO-66-NH2
[0092] UiO-66-NH2 is a metal-organic framework (MOF) molecular structure, and the specific preparation operation is as follows.
[0093] First, 110 mg of 2-aminoterephthalic acid, 1.9 g of benzoic acid, and 120 mg of zirconium tetrachloride were added to 10 mL of DNF and sonicated for 5 min to completely dissolve them;
[0094] Subsequently, the mixed solution was transferred into a 100 mL high-pressure reactor, and the reactor was tightened and placed in a forced air drying oven to react at 120°C for 24 h. After the reaction was completed, the mixture was naturally cooled to room temperature.
[0095] Then, the reactor was opened to take out the solution inside, centrifuged at 8000 rpm for 10 min, and the precipitate was washed with ethanol three times;
[0096] Finally, the precipitate after washing with ethanol was placed in a vacuum drying oven and dried at 65°C for 12 h, and the obtained material was a light yellow crystalline UiO-66-NH2 material.
[0097] (III) Preparation of UiO-66-NH2@siRNA
[0098] 1 mg of UiO-66-NH2 prepared in step (ii) and 500 nM of fluorescently modified siRNA (FAM-siRNA) prepared in step (i) were mixed and dissolved in DEPC water, and stirred at room temperature for 24 h to ensure that siRNA could be fully loaded on UiO-66-NH2;
[0099] Subsequently, the mixture was centrifuged at 8000 rpm for 10 min, and the precipitate was washed repeatedly with DEPC water for 3 times;
[0100] Finally, the cleaned sample was placed in a vacuum drying oven and dried at 65°C for 12 h to obtain UiO-66-NH2@siRNA nanoparticles loaded with siRNA.
[0101] (IV) Preparation of EVs@UiO-66-NH2@siRNA
[0102] The EVs (0.5 mg / mL) prepared in Example 1 and the UiO-66-NH2@siRNA nanoparticles (1 mg / mL) prepared in the above step (iii) were mixed with a pH=7.4 PBS solution and treated with ultrasound (ultrasonic frequency: 40KHZ) for 30 min;
[0103] Subsequently, the mixed solution was transferred into a liposome extruder and extruded through polycarbonate membranes with pore sizes of 800 nm, 400 nm, 200 nm and 100 nm, respectively; after repeating this extrusion operation 11 times (to ensure that the particle size of the relevant vesicles is uniform), the resulting extrudate solution was centrifuged at 12,000 rpm for 5 min, and the precipitate, namely EVs@UiO-66-NH2@siRNA nanoparticles, was further resuspended in PBS solution for later use.
[0104] During and after the preparation process, the inventors conducted detection and analysis from different angles on the relevant products, and the relevant circumstances are briefly introduced as follows.
[0105] (1) Particle size and potential detection analysis
[0106] For the prepared EVs, UiO-66-NH2, UiO-66-NH2@siRNA, and EVs@UiO-66-NH2@siRNA nanoparticles, they were sampled and dissolved in 1 mL of PBS. After ultrasonic treatment (40KHZ) for 1 min, they were placed in a measuring dish and the particle size and potential of the above four nanoparticles were tested using a Malvern nanoparticle size potentiometer.
[0107] Test results such as Figure 1 As shown. The analysis shows that:
[0108] (1) The average particle size of the extracted EVs was about 98.25 nm, and the average potential was about -20.91 mV;
[0109] (2) After loading with siRNA, the size of UiO-66-NH2 nanoparticles increased from 96.50 nm to 133.32 nm, and further increased to 171.79 nm after being coated with EVs;
[0110] (3) After UiO-66-NH2 was loaded with siRNA, the Zeta potential dropped from 26.96 mV to 18.35 mV due to the negative charge of siRNA. After being further coated by EVs, the Zeta potential further dropped to -22.23 mV, which is similar to the -21.91 mV of EVs, indicating that EVs successfully encapsulated UiO-66-NH2 nanoparticles.
[0111] (2) Electron microscopy (TEM) morphology analysis
[0112] Referring to the above instructions, 10 uL of EVs, UiO-66-NH2, UiO-66-NH2@siRNA, and EVs@UiO-66-NH2@siRNA solution samples were dropped on the polished surface of the copper grid, left to stand for 90 s, and then dropped with 2% uranyl acetate negative staining solution for 30 s in the dark. After absorbing the excess stain and leaving it in the dark for 1.5 h, transmission electron microscopy (TEM) was performed and photographed to observe its morphology, structure, and size.
[0113] Transmission electron microscopy photos Figure 2 As shown. The analysis shows that:
[0114] (a) The extracted EVs have a typical “cup-shaped” morphology and are approximately 70 nm in size.
[0115] (b) The size of UiO-66-NH2 and UiO-66-NH2@siRNA nanomaterials is about 90 nm and exhibits a relatively uniform shape and size;
[0116] (c) The size of EVs@UiO-66-NH2@siRNA is about 172.79 nm, and it exhibits a typical core-shell structure. Moreover, EVs can completely wrap and coat UiO-66-NH2@siRNA.
[0117] (3) Analysis of encapsulation efficiency of UiO-66-NH2@siRNA
[0118] In order to quantitatively evaluate the encapsulation efficiency (carrying rate) of siRNA in UiO-66-NH2, referring to the above operation, different concentrations (50 nM, 100 nM, 150 nM, 200 nM) of fluorescently modified FAM-siRNA were mixed with UiO-66-NH2 to prepare UiO-66-NH2@FAM-siRNA nanoparticles. Subsequently, the prepared UiO-66-NH2@FAM-siRNA nanoparticles were resuspended in a DEPC aqueous solution at pH = 3 for degradation to release FAM-siRNA. During the experiment, the fluorescence intensity of the supernatant (F1) was measured using a microplate reader (excitation / emission = 494 / 520 nm), and the encapsulation efficiency (carrying rate) was calculated by the difference in fluorescence intensity.
[0119] The formula for calculating the encapsulation efficiency (F%) is: F% = F1 / F0 × 100%;
[0120] F0 is the fluorescence intensity of the initial FAM-miR-34a solution.
[0121] The results are as follows Figure 3 As shown, it can be seen that UiO-66-NH2 can achieve efficient carrying of siRNA in a wide range of 50-200 nM.
[0122] (4) X-ray diffraction (XRD) analysis and specific surface area determination (BET)
[0123] The prepared UiO-66-NH2 and UiO-66-NH2@siRNA nanoparticles were subjected to XRD detection (characterization of crystal structure) and fully automatic specific surface area measurement. Figure 4 As shown. The analysis shows that:
[0124] After loading siRNA, the crystallinity of UiO-66-NH2 was almost unaffected, and this result indicated that the loading of siRNA would not have a significant effect on UiO-66-NH2;
[0125] The specific surface area measurement results based on the nitrogen adsorption-desorption curves show that compared with UiO-66-NH2, the surface area of UiO-66-NH2@siRNA is significantly reduced due to the occupation of siRNA in the cavity, which also shows that UiO-66-NH2 can effectively load siRNA.
[0126] Example 3
[0127] The inventors conducted further cell experiments using the materials prepared in Example 2. The relevant experimental results are briefly described as follows.
[0128] (I) Confocal laser scanning spectroscopy to observe cell uptake
[0129] Taking MC38 cells as an example, the inventors conducted an experimental test on the uptake of the relevant materials prepared in Example 2 by the cells. The specific operation is as follows.
[0130] First, place the frozen MC38 cells in a 37°C water bath and shake them to thaw quickly. After thawing, centrifuge at 1000rpm for 10 min, pour off the supernatant, add 1 mL of DMEM medium and mix well. After mixing, transfer the cell suspension to a culture bottle and add 4 mL of complete medium. Gently shake the culture bottle to spread the cells evenly in the culture bottle, and place it in a CO2 incubator at 37°C for constant temperature culture (change the culture medium every 1-2 days);
[0131] After that, when the cells have grown all over the culture flask, pour out the culture medium in the culture flask, add 2 mL PBS to rinse the cells twice, discard the PBS, add 1 mL trypsin to digest in the incubator for 5 min, and add 3 mL complete culture medium to terminate the trypsin digestion after digestion; after digestion, transfer to a centrifuge tube, centrifuge at 1000 rpm for 10 min, discard the supernatant, and add PBS to resuspend the cells;
[0132] Then, the resuspended cells were placed in a culture dish for laser confocal detection, with 4×10 4 cells, add 1 mL DMED medium, add UiO-66-NH2@FAM-siRNA and EVs@UiO-66-NH2@FAM-siRNA to the cells, respectively, with the amount of FAM-siRNA added being 0.5 nmol, and incubate for 3 h, 8 h, and 12 h respectively;
[0133] After incubation, discard the culture medium and wash with PBS (three times). After washing, add 1 mL of culture medium and 0.075 μL of LysoTracker and stain at 37°C for 30 min (lysosomes in cells are stained red);
[0134] After staining, the culture medium was discarded, the cells were washed with PBS (three times), fixed with 4% paraformaldehyde for 20 min, and then 1 μL DAPI was added and stained at 37°C for 30 min (blue staining of cell nuclei);
[0135] Finally, after washing with PBS (three times), laser confocal microscopy was performed.
[0136] The experimental results are as follows Figure 5 As shown. The analysis shows that:
[0137] After 3 h of incubation, the UiO-66-NH2@FAM-siRNA group showed only a small amount of cell uptake, a small amount of which co-localized with lysosomes; while in the EVs@UiO-66-NH2@FAM-siRNA group, it can be observed that the UiO-66-NH2@FAM-siRNA coated by EVs can be taken up by cells faster, which can be attributed to the better biocompatibility between EVs and the surface of tumor cell membranes, thus facilitating tumor cells to take up the UiO-66-NH2@FAM-siRNA coated by EVs;
[0138] After further incubation for 8 h, significant green fluorescence was observed in MC38 cells and co-localized with red fluorescence, which meant that a large amount of FAM-siRNA began to enter the lysosomes;
[0139] When the incubation continued for 12 h, it was observed that the green fluorescence was greatly enhanced and distributed in various parts of the cytosol, which indicated that the nanodelivery carrier was destroyed in the acidic environment and FAM-siRNA effectively escaped from the lysosome to the cytosol;
[0140] At the same time, since UiO-66-NH2@FAM-siRNA lacks EVs (biofilm) coating and has poor biocompatibility, it still exhibits a small amount of green fluorescence in the cells.
[0141] Subsequently, Image J software was used to quantitatively analyze the green fluorescence in MC38 cells. Figure 6 As shown in the figure, after 3 h, 8 h, and 12 h of co-incubation, the fluorescence intensity of the EVs@UiO-66-NH2@FAM-siRNA group was higher than that of the UiO-66-NH2@FAM-siRNA group, which once again showed that EVs-coated UiO-66-NH2@FAM-siRNA could improve the uptake efficiency of nanoparticles by MC38 cells.
[0142] In summary, EVs coated with UiO-66-NH2 can greatly improve the cell compatibility of MC38 cells and the uptake efficiency of siRNA.
[0143] 2. Flow cytometry analysis of cellular uptake
[0144] MC38 cells were plated in 6-well plates, with 5 × 10 41 mL of DMED medium was added to each well, and UiO-66-NH2@FAM-siRNA and EVs@UiO-66-NH2@FAM-siRNA were added to the cells, with the amount of FAM-siRNA added being 0.5 nmol, and incubated for 3 h, 8 h, and 12 h respectively. After incubation, the cells were washed twice with PBS, and 1 mL of trypsin was added to digest in a 37°C incubator for 5 min; 2 mL of DMEM medium was added to stop digestion, and the cell suspension was transferred to a 4 mL centrifuge tube and centrifuged at 1500 rpm for 5 min; the waste liquid was discarded, and 200uL of PBS was added to resuspend the cells, and finally the resuspended liquid was transferred to a flow cytometer tube for detection.
[0145] The results are as follows Figure 7 As shown in the figure, after 3 h, 8 h, and 12 h of co-incubation, the fluorescence intensity in both groups increased with the extension of incubation time, and the fluorescence intensity of the EVs@UiO-66-NH2@FAM-siRNA group was higher than that of the UiO-66-NH2@FAM-siRNA group, which was consistent with the results of laser confocal microscopy. Subsequently, the FAM fluorescence in the cells was quantitatively analyzed, and the results were shown in Figure 8 As shown, the results are the same Figure 7 The results shown are consistent, which once again shows that after EVs are coated, the cell compatibility and siRNA uptake efficiency of MC38 cells can be greatly improved.
[0146] 3. Effects on cell proliferation
[0147] The CCK-8 kit was used to detect and evaluate the effects of EVs, UiO-66-NH2, EVs@UiO-66-NH2 (prepared by referring to the operation of Example 2), UiO-66-NH2@siRNA, and EVs@UiO-66-NH2@siRNA nanoparticles prepared in Examples 1 and 2 on the proliferation of MC38 cells (i.e., the inhibitory effect on cell growth). The specific operation is as follows.
[0148] In a 96-well plate, 2 × 10 3 MC38 cells (100 mL DMEM medium per well) were cultured at 37°C until the cells adhered;
[0149] Subsequently, siRNA, EVs (added amount: 5 μg), EVs@UiO-66-NH2, UiO-66-NH2@siRNA, and EVs@UiO-66-NH2@siRNA nanoparticles were added to MC38 cells, and the added amount of siRNA was 200 nmol, calculated as siRNA;
[0150] After addition, the cells were incubated at 37 °C in an incubator for 24 h, 48 h, and 72 h, respectively;
[0151] After the incubation was completed, 10 μL of CCK-8 reagent was added and incubated for another 2 h;
[0152] Finally, the OD 450 nm value was measured in a microplate reader, and the absorbance value was proportional to the number of living cells.
[0153] The results are as follows Fig. 9 As shown. The analysis shows that:
[0154] After 24 h of incubation, there was no significant difference in cell proliferation, indicating that the nanoparticles themselves had no inhibitory effect on cells;
[0155] After 48 h of incubation, the proliferation of cells began to show obvious differences. The cell proliferation in the UiO-66-NH2@siRNA and EVs@UiO-66-NH2@siRNA groups slowed down, and the EVs@UiO-66-NH2@siRNA group was more obvious, while the other groups showed no significant differences compared with the siRNA control group.
[0156] After 72 hours of incubation, the proliferation of cells in the UiO-66-NH2@siRNA and EVs@UiO-66-NH2@siRNA groups continued to show significant differences, indicating that UiO-66-NH2@siRNA and EVs@UiO-66-NH2@siRNA continued to inhibit cells, while the other groups showed no significant differences compared with the siRNA control. The EVs@UiO-66-NH2@siRNA group showed a more obvious difference, which was attributed to the fact that after EVs coating, the nanoparticles could be recognized and taken up by cells more quickly, further improving the activity and inhibition efficiency of siRNA.
[0157] Next, after UiO-66-NH2@siRNA, EVs@UiO-66-NH2@siRNA and MC38 cells were co-incubated for 72 h, the absorbance value at OD 450 nm was quantitatively analyzed. Fig.10 As shown in Figure 2, the absorbance values of siRNA, EVs, UiO-66-NH2, and EVs@UiO-66-NH2 groups were maintained at around 1.4, the absorbance value of UiO-66-NH2@siRNA group decreased to around 0.9, and the absorbance value of EVs@UiO-66-NH2@siRNA group decreased to around 0.6. This result is consistent with Figure 8 The results shown were similar, further indicating that after EVs coating, the nanoparticles could be recognized and taken up by cells more quickly, further improving the activity and inhibition efficiency of siRNA.
Claims
1. An exosome loaded with MOF@siRNA, characterized in that: Prepared by the following steps:
1. Preparation of siRNA Design corresponding siRNA for the target site; 2. Preparation of compounds with MOF structure The compound having a MOF structure is UiO-66-NH2, (III) Preparation of MOF@siRNA The siRNA prepared in step (i) and the UiO-66-NH2 prepared in step (ii) are mixed and dissolved in water to allow the siRNA to be fully loaded on the UiO-66-NH2; After loading, the precipitate was collected by centrifugation, and the precipitate was cleaned and dried to obtain UiO-66-NH2@siRNA nanoparticles loaded with siRNA; 4. Extracellular vesicles (EVs) loaded with MOF@ siRNA Using probiotics as the source of extracellular vesicles EVs, preparing probiotic-derived extracellular vesicles EVs; The probiotics are Lactobacillus acidophilus; The prepared EVs and the UiO-66-NH2@siRNA nanoparticles prepared in the above step (iii) are dissolved in a buffer solution, and after being fully mixed, the mixed solution is transferred into a liposome extruder for extrusion. The obtained extrudate solution is centrifuged and the precipitate is retained to obtain the extracellular vesicles loaded with MOF@siRNA.
2. The MOF@siRNA-loaded exosome as claimed in claim 1, characterized in that: In step (I), the target site is the STAT3 site of colorectal cancer, and the corresponding siRNA sequence is designed as follows: The sense sequence is shown in SEQ ID No. 1, specifically: 5′- AAUUUUAAGCUGAUAAUUCAA-3′; The antisense sequence is shown in SEQ ID No. 2, specifically: 5'-GAAUUAUCAGCUUAAAAUUAA-3'; The target sequence was: 5'-TTGAATTATCAGCTTAAAATTAA-3'.
3. The MOF@siRNA-loaded exosome as claimed in claim 1, characterized in that: In step (ii), the preparation method of UiO-66-NH2 is as follows: First, 110 mg of 2-aminoterephthalic acid, 1.9 g of benzoic acid and 120 mg of zirconium tetrachloride were added to 10 mL of N, N-dimethylformamide and fully dissolved; Subsequently, the above solution was transferred to a reaction vessel and reacted at 120°C for 24 h; after the reaction was completed, it was naturally cooled to room temperature; Then, the reaction solution was centrifuged at 8000 rpm for 10 min to wash the precipitate; Finally, the washed precipitate was dried at 65 °C for 12 h to obtain a light yellow crystalline UiO-66-NH2 material.
4. The MOF@siRNA-loaded exosome as claimed in claim 1, characterized in that: In step (iii), when preparing UiO-66-NH2@siRNA, the material dosage ratio is: 1 mg of UiO-66-NH2: 500 nM of siRNA.
5. The MOF@siRNA-loaded exosome as claimed in claim 1, characterized in that: The specific preparation method of extracellular vesicles EVs derived from Lactobacillus acidophilus is as follows: (1) Recovery and initial expansion of strains After Lactobacillus acidophilus was revived in MRS solid medium, it was cultured to OD 600 = 0.8; (2) Extraction of extracellular vesicles (EVs) First, take 2000 mL of the bacterial solution amplified in step (1) above, centrifuge at 100,000 g for 30 min at 4°C, and discard the precipitate; Subsequently, the supernatant was centrifuged at 100,000 g for 60 min at 4°C, and the precipitate was retained; Then, the precipitate was resuspended in 5 mL of PBS solution and centrifuged again at 4°C and 100,000 g for 60 min to retain the precipitate; Finally, the precipitate was resuspended in 1 mL of PBS solution to obtain the Lactobacillus acidophilus EVs solution.
6. The MOF@siRNA-loaded exosomes according to claim 1, characterized in that: In step (iv), when preparing MOF@siRNA-loaded extracellular vesicles, the prepared EVs at 0.5 mg / mL and 1 mL were mixed with the UiO-66-NH2@siRNA nanoparticles at 1 mg / mL and 1 mL prepared in the above step (iii) using a PBS solution with pH = 7.4 and ultrasonically treated for 30 min.
7. Use of the MOF@siRNA-loaded exosomes according to claim 2 in the preparation of a drug for preventing and treating colorectal cancer.
